Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Savolitinib Alone and with Rifampicin in Healthy Subjects
NCT04118842Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Maximum plasma concentration and Area under the curve. Started Oct 2019; status: completed.
02
Drugs
savolitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04118842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118842.